ACRO Biomedical Co., Ltd. - Asset Resilience Ratio
ACRO Biomedical Co., Ltd. (6748) has an Asset Resilience Ratio of 60.44% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2024)
This chart shows how ACRO Biomedical Co., Ltd.'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down ACRO Biomedical Co., Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$367.20 Million | 60.44% |
| Total Liquid Assets | NT$367.20 Million | 60.44% |
Asset Resilience Insights
- Very High Liquidity: ACRO Biomedical Co., Ltd. maintains exceptional liquid asset reserves at 60.44% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
ACRO Biomedical Co., Ltd. Industry Peers by Asset Resilience Ratio
Compare ACRO Biomedical Co., Ltd.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for ACRO Biomedical Co., Ltd. (2020–2024)
The table below shows the annual Asset Resilience Ratio data for ACRO Biomedical Co., Ltd..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 46.88% | NT$307.20 Million | NT$655.33 Million | +41.98pp |
| 2023-12-31 | 4.89% | NT$35.07 Million | NT$716.74 Million | -3.89pp |
| 2022-12-31 | 8.78% | NT$35.01 Million | NT$398.53 Million | -11.51pp |
| 2021-12-31 | 20.30% | NT$30.71 Million | NT$151.28 Million | -14.66pp |
| 2020-12-31 | 34.96% | NT$71.11 Million | NT$203.43 Million | -- |
About ACRO Biomedical Co., Ltd.
ACRO Biomedical Co., Ltd. develops medical-grade regenerative biomaterials. The company offers products in the areas of wound care, orthopedics, dentistry, ophthalmology, cosmetic micro plastic surgery, beauty and eye care, and tissue engineering and regenerative medicines. The company was founded in 2014 and is based in Kaohsiung, Taiwan.